
Kevin E Weddington
Examiner (ID: 109, Phone: (571)272-0587 , Office: P/1629 )
| Most Active Art Unit | 1614 |
| Art Unit(s) | 1629, 2899, 1614, 1205 |
| Total Applications | 3386 |
| Issued Applications | 2180 |
| Pending Applications | 434 |
| Abandoned Applications | 815 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19447381
[patent_doc_number] => 20240307511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-19
[patent_title] => AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I
[patent_app_type] => utility
[patent_app_number] => 18/538866
[patent_app_country] => US
[patent_app_date] => 2023-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54255
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538866
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/538866 | AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I | Dec 12, 2023 | Pending |
Array
(
[id] => 19593104
[patent_doc_number] => 12150922
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-11-26
[patent_title] => Methods of inhibiting cyclooxygenase (COX) using tolterodine
[patent_app_type] => utility
[patent_app_number] => 18/533619
[patent_app_country] => US
[patent_app_date] => 2023-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4843
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18533619
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/533619 | Methods of inhibiting cyclooxygenase (COX) using tolterodine | Dec 7, 2023 | Issued |
Array
(
[id] => 19599459
[patent_doc_number] => 20240390339
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-28
[patent_title] => USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/529506
[patent_app_country] => US
[patent_app_date] => 2023-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10426
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529506
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/529506 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | Dec 4, 2023 | Pending |
Array
(
[id] => 19065607
[patent_doc_number] => 20240100033
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer
[patent_app_type] => utility
[patent_app_number] => 18/517512
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20144
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517512
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/517512 | Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer | Nov 21, 2023 | Abandoned |
Array
(
[id] => 19065634
[patent_doc_number] => 20240100060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 18/510986
[patent_app_country] => US
[patent_app_date] => 2023-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24908
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510986
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/510986 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Nov 15, 2023 | Abandoned |
Array
(
[id] => 19930310
[patent_doc_number] => 12303503
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2025-05-20
[patent_title] => Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain
[patent_app_type] => utility
[patent_app_number] => 18/510882
[patent_app_country] => US
[patent_app_date] => 2023-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5078
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510882
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/510882 | Use of dextromethorphan in combination with CYP2D6 and CYP3A4 enzyme inhibitors for the treatment of pain | Nov 15, 2023 | Issued |
Array
(
[id] => 19065576
[patent_doc_number] => 20240100002
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases
[patent_app_type] => utility
[patent_app_number] => 18/509114
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509114
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/509114 | Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases | Nov 13, 2023 | Pending |
Array
(
[id] => 19049270
[patent_doc_number] => 20240091239
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => ADMINISTRATION OF TESTOSTERONE COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/502166
[patent_app_country] => US
[patent_app_date] => 2023-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22888
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18502166
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/502166 | ADMINISTRATION OF TESTOSTERONE COMPOSITIONS | Nov 5, 2023 | Pending |
Array
(
[id] => 19441453
[patent_doc_number] => 12091695
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes
[patent_app_type] => utility
[patent_app_number] => 18/501967
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 24
[patent_no_of_words] => 10013
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501967
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501967 | Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes | Nov 2, 2023 | Issued |
Array
(
[id] => 19425293
[patent_doc_number] => 12084696
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-10
[patent_title] => Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes
[patent_app_type] => utility
[patent_app_number] => 18/501966
[patent_app_country] => US
[patent_app_date] => 2023-11-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 24
[patent_no_of_words] => 10014
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501966
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/501966 | Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes | Nov 2, 2023 | Issued |
Array
(
[id] => 19462319
[patent_doc_number] => 20240315988
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE
[patent_app_type] => utility
[patent_app_number] => 18/385468
[patent_app_country] => US
[patent_app_date] => 2023-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18149
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18385468
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/385468 | EUTECTIC FORMULATIONS OF CYCLOBENZAPRINE HYDROCHLORIDE AND AMITRIPTYLINE HYDROCHLORIDE | Oct 30, 2023 | Abandoned |
Array
(
[id] => 18986338
[patent_doc_number] => 20240058307
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 18/490993
[patent_app_country] => US
[patent_app_date] => 2023-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13796
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18490993
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/490993 | CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Oct 19, 2023 | Pending |
Array
(
[id] => 18986385
[patent_doc_number] => 20240058354
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
[patent_app_type] => utility
[patent_app_number] => 18/489685
[patent_app_country] => US
[patent_app_date] => 2023-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489685
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/489685 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | Oct 17, 2023 | Abandoned |
Array
(
[id] => 18972326
[patent_doc_number] => 20240052418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-15
[patent_title] => METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/483952
[patent_app_country] => US
[patent_app_date] => 2023-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -93
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18483952
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/483952 | METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | Oct 9, 2023 | Abandoned |
Array
(
[id] => 18953509
[patent_doc_number] => 20240041836
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4
[patent_app_type] => utility
[patent_app_number] => 18/477175
[patent_app_country] => US
[patent_app_date] => 2023-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477175
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/477175 | Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 | Sep 27, 2023 | Issued |
Array
(
[id] => 18901279
[patent_doc_number] => 20240016764
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-18
[patent_title] => HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE
[patent_app_type] => utility
[patent_app_number] => 18/373816
[patent_app_country] => US
[patent_app_date] => 2023-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6788
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18373816
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/373816 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | Sep 26, 2023 | Pending |
Array
(
[id] => 19924030
[patent_doc_number] => 12298308
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-13
[patent_title] => Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
[patent_app_type] => utility
[patent_app_number] => 18/466595
[patent_app_country] => US
[patent_app_date] => 2023-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 10483
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 163
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18466595
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/466595 | Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism | Sep 12, 2023 | Issued |
Array
(
[id] => 19387757
[patent_doc_number] => 20240277627
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-22
[patent_title] => NOVEL FLUOROCHEMICAL CARDIAC RESUSCITATION
[patent_app_type] => utility
[patent_app_number] => 18/460334
[patent_app_country] => US
[patent_app_date] => 2023-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460334
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/460334 | NOVEL FLUOROCHEMICAL CARDIAC RESUSCITATION | Aug 31, 2023 | Pending |
Array
(
[id] => 18842722
[patent_doc_number] => 20230405126
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => FORMULATIONS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/239195
[patent_app_country] => US
[patent_app_date] => 2023-08-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57102
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18239195
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/239195 | Formulations and uses thereof | Aug 28, 2023 | Issued |
Array
(
[id] => 18815892
[patent_doc_number] => 20230390231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-07
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING REPERFUSION INJURY OR HEMORRHAGE AFTER RECANALIZATION THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/235986
[patent_app_country] => US
[patent_app_date] => 2023-08-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10584
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18235986
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/235986 | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy | Aug 20, 2023 | Issued |